224 related articles for article (PubMed ID: 24015375)
1. Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.
Zhang W; Zheng Y; Hou L
Curr Genet Med Rep; 2013 Sep; 1(3):143-149. PubMed ID: 24015375
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of chemotherapeutic susceptibility and toxicity.
Moen EL; Godley LA; Zhang W; Dolan ME
Genome Med; 2012; 4(11):90. PubMed ID: 23199206
[TBL] [Abstract][Full Text] [Related]
3. Integrating Epigenomics into Pharmacogenomic Studies.
Zhang W; Huang RS; Dolan ME
Pharmgenomics Pers Med; 2008 Nov; 2008(1):7-14. PubMed ID: 20622972
[TBL] [Abstract][Full Text] [Related]
4. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.
Wheeler HE; Dolan ME
Pharmacogenomics; 2012 Jan; 13(1):55-70. PubMed ID: 22176622
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics discovery and implementation in genome-wide association studies era.
Ni X; Zhang W; Huang RS
Wiley Interdiscip Rev Syst Biol Med; 2013; 5(1):1-9. PubMed ID: 23188748
[TBL] [Abstract][Full Text] [Related]
6. Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.
Zhang W; Huang RS; Dolan ME
Trends Cancer Res; 2008; 4():1-13. PubMed ID: 21499559
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.
Zhang W; Dolan ME
Pharmacogenomics; 2010 Feb; 11(2):249-56. PubMed ID: 20136363
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic and pharmacogenomic discovery strategies.
Crisafulli C; Romeo PD; Calabrò M; Epasto LM; Alberti S
Cancer Drug Resist; 2019; 2(2):225-241. PubMed ID: 35582724
[TBL] [Abstract][Full Text] [Related]
9. Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.
Jack J; Rotroff D; Motsinger-Reif A
Curr Mol Med; 2014; 14(7):833-40. PubMed ID: 25109794
[TBL] [Abstract][Full Text] [Related]
10. Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines.
Niu N; Liu T; Cairns J; Ly RC; Tan X; Deng M; Fridley BL; Kalari KR; Abo RP; Jenkins G; Batzler A; Carlson EE; Barman P; Moran S; Heyn H; Esteller M; Wang L
Hum Mol Genet; 2016 Nov; 25(21):4819-4834. PubMed ID: 28173075
[TBL] [Abstract][Full Text] [Related]
11. PACdb: a database for cell-based pharmacogenomics.
Gamazon ER; Duan S; Zhang W; Huang RS; Kistner EO; Dolan ME; Cox NJ
Pharmacogenet Genomics; 2010 Apr; 20(4):269-73. PubMed ID: 20216476
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics and Personalized Medicine.
Cecchin E; Stocco G
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic biomarkers for personalized cancer treatment.
Rodríguez-Antona C; Taron M
J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.
Lauschke VM; Milani L; Ingelman-Sundberg M
AAPS J; 2017 Nov; 20(1):4. PubMed ID: 29181807
[TBL] [Abstract][Full Text] [Related]
15. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.
Stark AL; Zhang W; Mi S; Duan S; O'Donnell PH; Huang RS; Dolan ME
Pharmacogenomics J; 2010 Dec; 10(6):505-12. PubMed ID: 20142840
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic discovery using cell-based models.
Welsh M; Mangravite L; Medina MW; Tantisira K; Zhang W; Huang RS; McLeod H; Dolan ME
Pharmacol Rev; 2009 Dec; 61(4):413-29. PubMed ID: 20038569
[TBL] [Abstract][Full Text] [Related]
17. DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.
Arbitrio M; Di Martino MT; Scionti F; Agapito G; Guzzi PH; Cannataro M; Tassone P; Tagliaferri P
Oncotarget; 2016 Aug; 7(33):54028-54050. PubMed ID: 27304055
[TBL] [Abstract][Full Text] [Related]
18. Copy number variants and pharmacogenomics.
Ouahchi K; Lindeman N; Lee C
Pharmacogenomics; 2006 Jan; 7(1):25-9. PubMed ID: 16354122
[TBL] [Abstract][Full Text] [Related]
19. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.
Huang RS; Dolan ME
Pharmacogenomics; 2010 Apr; 11(4):471-4. PubMed ID: 20350124
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.
Arbitrio M; Di Martino MT; Scionti F; Barbieri V; Pensabene L; Tagliaferri P
High Throughput; 2018 Dec; 7(4):. PubMed ID: 30567415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
